Registered in England and Wales
Company Number: 00598696

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to the action you should take, you are recommended to seek your own financial advice from your stockbroker, bank manager, solicitor, accountant, or other independent adviser authorised under the Financial Services and Markets Act 2000 if you are resident in the UK or, if you reside elsewhere, another appropriately authorised financial adviser.

If you have recently sold or transferred all of your shares in Feedback plc, please send this notice and the accompanying documents as soon as possible to the purchaser or transferee or to the person who arranged the sale or transfer, so they can pass these documents to the person who now holds the shares.

FEEDBACK PLC

Registered in England and Wales with Company Number 00598696

NOTICE OF ANNUAL GENERAL MEETING

Registered in England and Wales
Company Number: 00598696

LETTER FROM THE CHAIRMAN

Registered Office: 201 Temple Chambers
3-7 Temple Avenue
London
EC4Y 0DT

6 November 2026

Dear Shareholder

Annual General Meeting 2026

The Board is pleased to confirm that the Annual General Meeting (**AGM**) of Feedback plc (**Company**) will take place at 11:00 a.m. on Monday, 30 November 2026. The notice convening the AGM (**AGM Notice**) is set out at the end of this letter.

Arrangements

The AGM will be held at the offices of DAC Beachcroft LLP, Woolgate, 25 Basinghall Street, London, EC2V 5HA.

Questions can be submitted by email to feedbackplc@walbrookpr.com. Please title your email "FDBK – AGM Shareholder Questions" and include your full name. The Company reserves the right to respond only to questions put by shareholders whose names are on the Company's register of members at 11.00 a.m. on Thursday, 26 November 2026.

Matters for consideration at the AGM

Resolutions

The resolutions to be put to shareholders at the AGM are set out in the AGM Notice which is included with this letter. An explanation of each of the resolutions is set out at the end of the document.

Section 656 of the Companies Act - Serious Loss of Capital

In circumstances where the value of the Company's net assets falls below half (or less) of its called-up share capital (constituting a "serious loss of capital" under the Companies Act 2006 (**CA 2006**)), its Directors are required, pursuant to section 656 of CA 2006, to convene a general meeting of the Company for the purpose of allowing shareholders to consider whether any, and, if so, what, steps should be taken to deal with the situation. As the AGM was already set to be convened, the Directors do not believe it necessary to convene a separate general meeting to consider the serious loss of capital matter as it can be considered at the AGM. The Board welcomes dialogue with the Company's shareholders, and the AGM will provide a forum for such discussions to take place. The Board do not consider it necessary to propose a specific resolution in relation to the serious loss of capital and shareholders will not be asked to vote on this matter at the AGM. The Board will continue to prudently manage the Company's cash reserves and minimise its operating expenses whilst it continues its future strategy.

Annual Report and Accounts

The Annual Report and Accounts for the year ended 31 May 2026 are available on the Company's website: https://feedbackmedical.com/investors and will be sent separately to shareholders within the timeframe required by CA 2006.

Voting

Shareholders are encouraged to vote on the resolutions to be put to the AGM by proxy whether or not they intend to attend. Please also refer to the "Notes" section of the AGM Notice for details on how to vote by proxy.

Voting at the AGM will be conducted on a poll in accordance with best practice.

Recommendation

The Board of Feedback plc considers all of the proposed resolutions to be in the best interests of the Company and shareholders as a whole and, accordingly, recommends that shareholders vote in favour of all the resolutions proposed, as the directors intend to do in respect of their own holdings.

We look forward to welcoming shareholders to the AGM.

Yours faithfully

Professor Rory Shaw
Chair

Registered in England and Wales
Company Number: 00598696

FEEDBACK PLC
NOTICE OF ANNUAL GENERAL MEETING
2026

Notice is hereby given that the Annual General Meeting (**AGM**) of Feedback plc will be held at the offices of DAC Beachcroft LLP, Woolgate, 25 Basinghall Street, London, EC2V 5HA on Monday, 30 November 2026 at 11:00 a.m. to consider and, if thought fit, to pass the resolutions set out below. Resolutions 1 to 11 will be proposed as ordinary resolutions and resolutions 12 and 13 will be proposed as special resolutions.

Definitions

CA 2006	the Companies Act 2006
Company	Feedback plc
Directors	the board of directors of the Company (or a duly constituted committee thereof)
Equity Securities	shall have the meaning given in section 560 of CA 2006
Ordinary Shares	ordinary shares in the capital of the Company

ORDINARY RESOLUTIONS

Report and Accounts

1. To receive the Annual Report and Accounts of the Company for the year ended 31 May 2026 together with the Directors' reports and auditor's report on those accounts.

Remuneration Report

2. To accept the Directors' Remuneration Report for the financial year ended 31 May 2026 as set out on pages 51 to 54 of the Company's Annual Report and Accounts for the year ended 31 May 2026.

Directors

3. To re-elect Adam Denning as a director of the Company.
4. To re-elect Annemijn Eschauzier as a director of the Company.
5. To re-elect Dr. Tom Oakley as a director of the Company.
6. To elect Emma Oswick as a director of the Company.
7. To re-elect Philipp Prince as a director of the Company.
8. To re-elect Professor Rory Shaw as a director of the Company.

Auditor

9. To re-appoint Price Bailey LLP as auditor of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company.
10. To authorise the Directors to determine the fees payable to the auditor.
11. THAT, in accordance with section 551 of CA 2006, the Directors be generally and unconditionally authorised to allot Equity Securities:

11.1. up to an aggregate nominal amount of £292,098.52 (such amount to be reduced by the nominal amount of any Equity Securities allotted pursuant to the authority in paragraph 11.2 below) in connection with a fully pre-emptive offer:

A. to holders of Ordinary Shares in proportion (as nearly as may be practicable) to their respective holdings; and

B. to holders of other Equity Securities as required by the rights of those securities or as the Directors otherwise consider necessary,

but subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates, legal or practical problems in or under the laws of any territory or the requirements of any regulatory body or stock exchange; and

11.2. in any other case, up to an aggregate nominal amount of £146,049.26 (such amount to be reduced by the nominal amount of any Equity Securities allotted pursuant to the authority in paragraph 11.1 above in excess of £146,049.26),

provided that this authority shall, unless renewed, varied or revoked by the Company, expire at the conclusion of the next annual general meeting of the Company (or if earlier, the date which is 15 months from the date of the passing of the resolution) save that the Company may, before such expiry, make offers or agreements which would or might require Equity Securities to be allotted and the Directors may allot Equity Securities in pursuance of such offer or agreement notwithstanding that the authority conferred by this resolution has expired.

This resolution revokes and replaces all unexercised authorities previously granted to the Directors under section 551 of CA 2006, but without prejudice to any allotment of shares or grant of rights already made, offered or agreed to be made pursuant to such authorities.

SPECIAL RESOLUTIONS

12. THAT, subject to the passing of resolution 11, the Directors be authorised to allot Equity Securities for cash under the authority conferred by that resolution and/or to sell Ordinary Shares held by the Company as treasury shares for cash as if section 561 of CA 2006 did not apply to any such allotment or sale, provided that such authority shall be limited to:

12.1. the allotment of Equity Securities in connection with an offer of Equity Securities (but, in the case of the authority granted under paragraph 11.1 above, by way of a fully pre-emptive offer only):

A. to the holders of Ordinary Shares in proportion (as nearly as may be practicable) to their respective holdings; and

B. to holders of other Equity Securities as required by the rights of those securities or as the Directors otherwise consider necessary,

but subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates, legal or practical problems in or under the laws of any territory or the requirements of any regulatory body or stock exchange; and

12.2. the allotment of Equity Securities or sale of treasury shares (otherwise than pursuant to paragraph 12.1 of this resolution) to any person up to an aggregate nominal amount of £43,814.77; and

12.3. the allotment of Equity Securities or sale of treasury shares (otherwise than under paragraph 12.1 or paragraph 12.2 above) up to a nominal amount equal to 20% of any allotment of Equity Securities or sale of treasury shares from time to time under paragraph 12.2 above, such authority to be used only for the purposes of making a follow-on offer which the Directors determine to be of a kind contemplated by

paragraph 3 of Section 2B of the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this notice,

such authority to expire at the conclusion of the Company's next annual general meeting after the passing of this resolution or, if earlier, at the close of business on the date which is 15 months from the date of passing the resolution, save that the Company may, before such expiry make offers or agreements which would or might require Equity Securities to be allotted (or treasury shares to be sold) after the authority expires and the Directors may allot Equity Securities (or sell treasury shares) in pursuance of any such offer or agreement as if the authority had not expired.

13. THAT, subject to the passing of resolution 11, the Directors be authorised in addition to any authority granted under resolution 12 to allot Equity Securities for cash under the authority conferred by resolution 11 and/or to sell Ordinary Shares held by the Company as treasury shares as if section 561 of CA 2006 did not apply to any such allotment or sale, provided that such authority shall be:

    13.1. limited to the allotment of Equity Securities or sale of treasury shares up to an aggregate nominal amount of £43,814.77, such authority to be used only for the purpose of financing (or refinancing, if the authority is to be used within 12 months after the original transaction) a transaction which the Directors determine to be an acquisition or other capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this notice; and

    13.2. limited to the allotment of Equity Securities or sale of treasury shares (otherwise than under paragraph 13.1 above) up to a nominal amount equal to 20% of any allotment of Equity Securities or sale of treasury shares from time to time under paragraph 13.1 above, such authority to be used only for the purposes of making a follow-on offer which the Directors determine to be of a kind contemplated by paragraph 3 of Section 2B of the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this notice,

    such authority to expire at the conclusion of the Company's next annual general meeting after the passing of this resolution or, if earlier, at the close of business on the date which is 15 months from the date of passing the resolution but, in each case, prior to its expiry the Company may make offers, and enter into agreements, which would, or might, require Equity Securities to be allotted (and treasury shares to be sold) after the authority expires and the Directors may allot Equity Securities (and sell treasury shares) under any such offer or agreement as if the authority had not expired.

SHAREHOLDER DISCUSSION

To consider, pursuant to section 656(1) of CA 2006, whether any and, if so, what steps should be taken to address the serious loss of capital within the Company.

BY ORDER OF THE BOARD

One Advisory Limited

One Advisory Limited
Company Secretary

6 November 2026

201 Temple Chambers
3-7 Temple Avenue
London
EC4Y 0DT

NOTES TO THE NOTICE OF AGM

Entitlement to Attend and Vote at the AGM

1. The Company specifies that only those members registered on the Company's register of members 48 hours before the meeting or, if the meeting is adjourned, 48 hours prior to the adjourned meeting shall be entitled to attend and vote at the meeting.

2. Voting at the AGM will be conducted by way of a poll rather than on a show of hands. The Board believes a poll is more representative of shareholders' voting intentions because shareholders' votes are counted according to the number of shares held and all votes tendered are taken into account.

3. The total of the votes cast by shareholders for or against or withheld on each resolution will be announced via a Regulatory Information Service and published on the Company's investor website, feedbackmedical.com/investors/, after the AGM.

Proxy Voting – General

4. If you are a shareholder of the Company at the time set out in Note 1 above, you are entitled to appoint a proxy to exercise all or any of your rights to attend, speak and vote at the meeting. You can only appoint a proxy using the procedures set out in these notes. You can appoint the Chair of the meeting as your proxy or another person of your choice. Your proxy does not need to be a member of the Company but must attend the meeting to represent you.

5. You may appoint more than one proxy provided each proxy is appointed to exercise rights attached to different shares. You may not appoint more than one proxy to exercise rights attached to any one share.

6. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first-named being the most senior).

7. Appointment of a proxy does not preclude you from attending the general meeting and voting in person. If you do vote in person at the meeting, that vote will override any votes previously submitted in respect of those shares.

8. A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against a resolution. If you do not select a voting option, your proxy may vote or abstain from voting at their discretion.

Proxy Voting – Procedures

9. To be valid proxy votes must be received by 11:00 a.m. on Thursday, 26 November 2026, or if the meeting is adjourned, 48 hours (excluding any part of a day that is not a working day) before the adjourned meeting (**Proxy Vote Closing Time**).

10. A proxy form may be used to make such appointment and give proxy instructions. If you do not have a proxy form and believe that you should have one, or if you require additional forms, please contact Share Registrars Limited:

    - Tel: +44 (0) 1252 821390. Lines are open from 9:00 am to 5:00 pm (UK time) Monday to Friday (excluding public holidays in England and Wales).
    - Address: Share Registrars Limited, 3 The Millennium Centre, Crosby Way, Farnham, Surrey GU9 7XX.
    - Email: enquiries@sharegistrars.uk.com

11. To be valid any proxy form or other instrument appointing a proxy must be received:

    - by post at Share Registrars Limited, 3 The Millennium Centre, Crosby Way, Farnham, Surrey GU9 7XX no later than the Proxy Vote Closing Time; or

- in the case of shareholders holding their shares through CREST, by utilising the CREST electronic proxy appointment service in accordance with the procedures set out in paragraphs 14 to 17 below; and no later than the Proxy Vote Closing Time; or
- As an alternative to submitting a hard copy proxy form, you may submit your proxy electronically by visiting www.shareregistrars.uk.com, clicking on the "Proxy Vote" button and then following the on-screen instructions. For an electronic proxy appointment to be valid, your appointment must be received no later than the Proxy Vote Closing Time.

12. In the case of a member which is a company, the proxy form must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company.
13. Any power of attorney or any other authority under which the proxy form is signed (or a duly certified copy of such power or authority) must be included with the proxy form.
14. CREST members may vote by utilising the CREST electronic proxy appointment service in accordance with the procedures set out below.
15. CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for the meeting (and any adjournment of the meeting) by using the procedures described in the CREST Manual (available from www.euroclear.com). CREST Personal Members or other CREST sponsored members, and those CREST members who have appointed a service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.
16. In order for a proxy appointment or instruction made by means of CREST to be valid, the appropriate CREST message (a 'CREST Proxy Instruction') must be properly authenticated in accordance with Euroclear UK & International Limited's specifications and must contain the information required for such instructions, as described in the CREST Manual. The message must be transmitted so as to be received by the issuer's agent (ID 7RA36) by the Proxy Vote Closing Time. For this purpose, the time of receipt will be taken to mean the time (as determined by the timestamp applied to the message by the CREST application host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time, any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.
17. CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear UK & International Limited does not make available special procedures in CREST for any particular message. Normal system timings and limitations will, therefore, apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member, or sponsored member, or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting system providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings. The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

Proxy Voting – Changes and Revocations

18. To change your proxy instructions simply submit a new proxy appointment using the methods set out above. Note that the Proxy Vote Closing Time also applies in relation to amended instructions; any amended proxy appointment received after the Proxy Vote Closing Time will be disregarded. Where you have appointed a proxy using the hard copy proxy form and would like to change the instructions using another hard copy proxy form, please contact Share Registrars Limited via the methods set out in Note 10 above. If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.

19. In order to revoke a proxy instruction, you will need to inform the Company by contacting Share Registrars using the contact details in Note 10 above.

20. In the case of a member which is a company, the revocation notice must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the revocation notice is signed (or a duly certified copy of such power or authority) must be included with the revocation notice. The revocation notice must be received by Share Registrars Limited no later than the Proxy Vote Closing Time. If you attempt to revoke your proxy appointment but the revocation is received after the time specified then, subject to Note 7 above, your proxy appointment will remain valid.

Corporate Representatives

21. A corporation which is a member can appoint one or more corporate representatives who may exercise, on its behalf, all its powers as a member provided that no more than one corporate representative exercises power over the same share.

22. Corporate representatives must produce a signed corporate representative letter from the shareholder in suitable form at the AGM together with photographic identification to verify they are the representative referred to in the letter.

Share Capital

23. As at the close of business on the day immediately before the date of this notice of general meeting, the Company's issued share capital comprised 43,814,779 Ordinary Shares of nominal value 1 pence each. No shares are held in treasury. Each Ordinary Share carries the right to one vote at a general meeting of the Company and, therefore, the total number of voting rights in the Company as at close of business, on the day immediately before the date of this notice of general meeting is 43,814,779.

Personal Data

24. Your personal data includes all data provided by you, or on your behalf, which relates to you as a shareholder, including your name and contact details, the votes you cast and your Shareholder Reference Number (attributed to you by the Company). The Company determines the purposes for which and the manner in which your personal data is to be processed. The Company and any third party to which it discloses the data (including the Company's Registrar) may process your personal data for the purposes of compiling and updating the Company's records, fulfilling its legal obligations and processing the shareholder rights you exercise. A copy of the Company's privacy policy can be found online at feedbackmedical.com.

EXPLANATORY NOTES

Resolutions 1 to 11 are ordinary resolutions and require a simple majority of votes cast to be in favour in order to be passed. Resolutions 12 and 13 are special resolutions and require at least 75% of votes cast to be in favour in order to be passed.

Resolution 1 – Report and Accounts (Ordinary Resolution)
Section 437 of CA 2006 requires the Directors to lay copies of the Company's annual report and accounts for the year ended 31 May 2026 before the Company in general meeting before the end of the period for filing them with Companies House. This resolution addresses that requirement. The Company's Annual Report and Accounts are available on the Company's website: https://feedbackmedical.com/investors and will be sent separately to shareholders within the timeframe required by CA 2006.

Resolutions 2 – Remuneration (Ordinary Resolutions)
Resolution 2 requests that shareholders accept the Directors' Remuneration Report (**DRR**). Although this resolution is not binding, the Directors wish to give shareholders the opportunity to express their views in relation to directors' remuneration in an appropriate manner. This resolution is intended to provide that opportunity. The DRR is backwards-looking and sets out the directors' remuneration in respect of the year ended 31 May 2026.

Resolutions 3 to 8 – Directors (Ordinary Resolutions)
In accordance with best corporate governance practice, all Directors at the time of this Notice are retiring at the AGM and being willing, put themselves forward for re-election by shareholders. Emma Oswick was appointed a director subsequent to the 2025 AGM and accordingly, will be seeking election by the shareholders.

Biographical details of all Directors can be found on pages 36 to 38 in the Company's Annual Report and Accounts for the year ended 31 May 2026.

Resolutions 9 and 10 – Auditor (Ordinary Resolutions)
On the recommendation of the Audit and Risk Committee, the Board proposes as resolution 9 that Price Bailey LLP be re-appointed as auditor of the Company. Resolution 10 proposes that the Board be authorised to determine the level of the auditor's remuneration. For further information, please refer to the Audit and Risk Committee Report in the Company's Annual Report and Accounts for the year ended 31 May 2026.

Resolution 11 – Authority to Allot (Ordinary Resolution)
This resolution deals with the Directors' authority to allot securities in accordance with section 551 of the CA 2006 and complies with the Investment Association Share Capital Management Guidelines issued in February 2023.

If passed, the resolution will authorise the Directors to allot:

(i) Equity Securities up to a maximum nominal amount of £292,098.52 which represents approximately two thirds of the Company's issued Ordinary Shares as at 4 November 2026 (being the latest practicable date prior to publication of this document) (**ISC**) in relation to a fully pre-emptive offer, with authority for the Directors to deal pragmatically with legal, regulatory and logistical issues (e.g. fractions of shares and overseas securities laws). This maximum is reduced by the nominal amount of any Equity Securities allotted under the authority set out in paragraph 11.2 of the resolution; and

(ii) Equity Securities up to a maximum nominal amount of £146,049.26 otherwise which represents approximately one third of the Company's ISC. This amount will be reduced to the extent that Equity Securities allotted pursuant to paragraph 11.1 exceed £146,049.26 in nominal value.

The maximum nominal amount of securities which may be allotted under this resolution is therefore £292,098.52.

The authority granted by this resolution will expire on the earlier of the conclusion of next year's annual general meeting and the date which is 15 months after the resolution is passed.

Resolutions 12 and 13 – Disapplication of Statutory Pre-Emption Rights (Special Resolutions)

Under CA 2006, the Directors require shareholder authority to issue Equity Securities for cash without first offering them to the whole shareholder base pro rata to their existing holdings in accordance with the statutory requirements of section 561 CA 2006. Resolutions 12 and 13 will, if passed, give the Directors this authority within the specified limitations. Resolution 12 provides a general authority and resolution 13 is in respect of allotments to finance acquisitions and capital investments.

These resolutions are in line with the Pre-Emption Group's Statement of Principles 2022, the template resolutions published by the Pre-Emption Group in 2022 and the Share Capital Management Guidelines published by the Investment Association (as updated in February 2023) (**Investor Guidelines**). The Company notes the increase in the acceptable levels of authority set out in the Pre-Emption Group's Statement of Principles 2022 and the Directors consider it appropriate for the Company to seek those enhanced approvals to maximise its ability to act swiftly in the interests of shareholders should a need or opportunity arise.

Put simply, the Directors will, if the resolutions are passed, have authority to freely allot up to 10% of the ISC for cash, with additional allotments for cash permitted only for:

- offers which are essentially pre-emptive but enable the Directors to make pragmatic decisions to deal with logistical and regulatory issues in connection with the offer (up to two thirds ISC in total);
- financing specified investments and acquisitions in line with the Investor Guidelines (up to 10% ISC); and
- specified follow-on offers in line with the Investor Guidelines (up to 20% of the nominal value of shares allotted under the original offer process (maximum 2% of the ISC)).

The authorities set out in these resolutions will expire on the conclusion of next year's annual general meeting or, if earlier, on the date which is 15 months after the date the resolutions are passed.